Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 65 to 80% |
Protein binding | < 4% |
Metabolism | To apricitabine triphosphate |
Elimination half-life | 6 to 7 hours (triphosphate) |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H11N3O3S |
Molar mass | 229.25 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Apricitabine (INN, codenamed AVX754 and SPD754, sometimes abbreviated to ATC) is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine.